CR20210463A - Inhibidores de arginasa y métodos de uso de estos - Google Patents
Inhibidores de arginasa y métodos de uso de estosInfo
- Publication number
- CR20210463A CR20210463A CR20210463A CR20210463A CR20210463A CR 20210463 A CR20210463 A CR 20210463A CR 20210463 A CR20210463 A CR 20210463A CR 20210463 A CR20210463 A CR 20210463A CR 20210463 A CR20210463 A CR 20210463A
- Authority
- CR
- Costa Rica
- Prior art keywords
- methods
- arginase inhibitors
- arginase
- inhibitors
- Prior art date
Links
- 102000004452 Arginase Human genes 0.000 title 1
- 108700024123 Arginases Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se divulgan compuestos de fórmula (Ib) o (Vc), o una sal farmacéuticamente aceptable de estos, composiciones farmacéuticas que comprenden compuestos de fórmula (Ib) o (Vc) y métodos para utilizar estos para tratar el cáncer, una enfermedad inflamatoria respiratoria e inhibir la arginasa: donde R1 es -H o -C(O)CH(R1a)NHR1b; y R1a se selecciona entre -H, -alquilo (C1-C4) y CH2OR1c; R1b es -H; o como alternativa, R1a y R1b, junto con el átomo al que están unidos, forman un anillo heterocíclico de 5 miembros; y R1c es H o -CH3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802765P | 2019-02-08 | 2019-02-08 | |
| PCT/IB2020/050982 WO2020161675A1 (en) | 2019-02-08 | 2020-02-07 | Arginase inhibitors and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20210463A true CR20210463A (es) | 2021-10-15 |
Family
ID=69770954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20210463A CR20210463A (es) | 2019-02-08 | 2020-02-07 | Inhibidores de arginasa y métodos de uso de estos |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20220106335A1 (es) |
| EP (1) | EP3921033B1 (es) |
| JP (1) | JP2022521474A (es) |
| KR (1) | KR20210126044A (es) |
| CN (1) | CN113395996B (es) |
| AU (1) | AU2020218651B2 (es) |
| BR (1) | BR112021015581A2 (es) |
| CA (1) | CA3127755A1 (es) |
| CL (1) | CL2021002056A1 (es) |
| CO (1) | CO2021011039A2 (es) |
| CR (1) | CR20210463A (es) |
| DK (1) | DK3921033T3 (es) |
| DO (1) | DOP2021000166A (es) |
| EA (1) | EA202192114A1 (es) |
| ES (1) | ES2960034T3 (es) |
| FI (1) | FI3921033T3 (es) |
| HR (1) | HRP20231092T1 (es) |
| HU (1) | HUE062968T2 (es) |
| IL (1) | IL285108A (es) |
| LT (1) | LT3921033T (es) |
| MA (1) | MA56324B1 (es) |
| MX (1) | MX2021009499A (es) |
| PE (1) | PE20220280A1 (es) |
| PL (1) | PL3921033T3 (es) |
| PT (1) | PT3921033T (es) |
| RS (1) | RS64781B1 (es) |
| SG (1) | SG11202108503PA (es) |
| SI (1) | SI3921033T1 (es) |
| WO (1) | WO2020161675A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202228720A (zh) | 2020-12-22 | 2022-08-01 | 波蘭商昂科艾倫迪治療法股份公司 | 精胺酸酶抑制劑及其使用方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9901572D0 (sv) * | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
| SE0300907D0 (sv) * | 2003-03-31 | 2003-03-31 | Astrazeneca Ab | Novel compounds |
| CA2749853C (en) * | 2009-01-26 | 2018-08-21 | Trustees Of The University Of Pennsylvania | Arginase inhibitors and methods of use |
| KR101931822B1 (ko) * | 2010-04-22 | 2018-12-24 | 마아즈, 인코오포레이티드 | 아르기나아제의 억제제와 그것의 치료적 적용 |
| EP3034509B1 (en) * | 2010-10-26 | 2020-04-22 | Mars, Incorporated | Arginase inhibitors as therapeutics |
| AU2012326109A1 (en) * | 2011-10-19 | 2014-05-29 | Mars, Incorporated | Inhibitors of arginase and their therapeutic applications |
| EP3428153A1 (en) * | 2012-12-17 | 2019-01-16 | Parion Sciences, Inc. | 3,5-diamino-6-chloro-n-(n-(4-phenylbutyl)carbamimidoyl) pyrazine-2- carboxamide compounds |
| PL410665A1 (pl) * | 2014-12-29 | 2016-07-04 | Oncoarendi Therapeutics Spółka Z Ograniczoną Odpowiedzialnością | Inhibitory arginazy oraz ich zastosowania terapeutyczne |
| WO2017175185A1 (en) * | 2016-04-08 | 2017-10-12 | Novartis Ag | Heteroaryl butanoic acid derivatives as lta4h inhibitors |
| PT3559009T (pt) * | 2016-12-22 | 2021-05-04 | Calithera Biosciences Inc | Composições e métodos para inibir a atividade da arginase |
| CN108794517B (zh) * | 2017-04-27 | 2021-03-30 | 南京谷睿生物科技有限公司 | 一种精氨酸酶抑制剂及其制备方法与用途 |
| WO2019205979A1 (zh) * | 2018-04-27 | 2019-10-31 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、包含其的药物组合物及其制备方法和用途 |
-
2020
- 2020-02-07 PE PE2021001295A patent/PE20220280A1/es unknown
- 2020-02-07 MA MA56324A patent/MA56324B1/fr unknown
- 2020-02-07 PL PL20709706.4T patent/PL3921033T3/pl unknown
- 2020-02-07 AU AU2020218651A patent/AU2020218651B2/en active Active
- 2020-02-07 EP EP20709706.4A patent/EP3921033B1/en active Active
- 2020-02-07 KR KR1020217028170A patent/KR20210126044A/ko not_active Application Discontinuation
- 2020-02-07 SG SG11202108503PA patent/SG11202108503PA/en unknown
- 2020-02-07 HR HRP20231092TT patent/HRP20231092T1/hr unknown
- 2020-02-07 PT PT207097064T patent/PT3921033T/pt unknown
- 2020-02-07 JP JP2021546232A patent/JP2022521474A/ja active Pending
- 2020-02-07 CA CA3127755A patent/CA3127755A1/en active Pending
- 2020-02-07 US US17/429,011 patent/US20220106335A1/en active Pending
- 2020-02-07 EA EA202192114A patent/EA202192114A1/ru unknown
- 2020-02-07 WO PCT/IB2020/050982 patent/WO2020161675A1/en active Application Filing
- 2020-02-07 RS RS20230898A patent/RS64781B1/sr unknown
- 2020-02-07 MX MX2021009499A patent/MX2021009499A/es unknown
- 2020-02-07 ES ES20709706T patent/ES2960034T3/es active Active
- 2020-02-07 CN CN202080012567.4A patent/CN113395996B/zh active Active
- 2020-02-07 LT LTEPPCT/IB2020/050982T patent/LT3921033T/lt unknown
- 2020-02-07 BR BR112021015581-3A patent/BR112021015581A2/pt unknown
- 2020-02-07 DK DK20709706.4T patent/DK3921033T3/da active
- 2020-02-07 FI FIEP20709706.4T patent/FI3921033T3/fi active
- 2020-02-07 HU HUE20709706A patent/HUE062968T2/hu unknown
- 2020-02-07 CR CR20210463A patent/CR20210463A/es unknown
- 2020-02-07 SI SI202030267T patent/SI3921033T1/sl unknown
-
2021
- 2021-07-25 IL IL285108A patent/IL285108A/en unknown
- 2021-08-04 CL CL2021002056A patent/CL2021002056A1/es unknown
- 2021-08-06 DO DO2021000166A patent/DOP2021000166A/es unknown
- 2021-08-23 CO CONC2021/0011039A patent/CO2021011039A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2021000166A (es) | 2021-09-30 |
| US20220106335A1 (en) | 2022-04-07 |
| DK3921033T3 (da) | 2023-10-16 |
| BR112021015581A2 (pt) | 2021-10-05 |
| AU2020218651A1 (en) | 2021-09-30 |
| JP2022521474A (ja) | 2022-04-08 |
| SI3921033T1 (sl) | 2023-11-30 |
| AU2020218651B2 (en) | 2023-01-12 |
| MX2021009499A (es) | 2021-09-08 |
| WO2020161675A1 (en) | 2020-08-13 |
| EA202192114A1 (ru) | 2021-12-01 |
| HUE062968T2 (hu) | 2023-12-28 |
| RS64781B1 (sr) | 2023-11-30 |
| MA56324B1 (fr) | 2023-10-31 |
| SG11202108503PA (en) | 2021-09-29 |
| CN113395996B (zh) | 2024-05-28 |
| CO2021011039A2 (es) | 2021-09-09 |
| PE20220280A1 (es) | 2022-02-25 |
| FI3921033T3 (fi) | 2023-09-15 |
| EP3921033A1 (en) | 2021-12-15 |
| CL2021002056A1 (es) | 2022-03-04 |
| PL3921033T3 (pl) | 2024-01-15 |
| CA3127755A1 (en) | 2020-08-13 |
| LT3921033T (lt) | 2023-09-25 |
| PT3921033T (pt) | 2023-10-11 |
| HRP20231092T1 (hr) | 2023-12-22 |
| IL285108A (en) | 2021-09-30 |
| ES2960034T3 (es) | 2024-02-29 |
| KR20210126044A (ko) | 2021-10-19 |
| CN113395996A (zh) | 2021-09-14 |
| EP3921033B1 (en) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3743063A4 (en) | CBL-B INHIBITORS AND METHOD OF USING THEREOF | |
| MX2021003559A (es) | Inhibidores de vap-1. | |
| EP3765006A4 (en) | ARGINASE INHIBITORS AND METHODS OF USE | |
| IL276711A (en) | Arginase inhibitors and methods of using them | |
| EP3810617A4 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| EP3962481A4 (en) | KCNT1 INHIBITORS AND METHODS OF USE | |
| EP3962479A4 (en) | KCNT1 INHIBITORS AND METHODS OF USE | |
| IL284640A (en) | PCSK9 inhibitors and methods of using them | |
| MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| EP3810615A4 (en) | ARGINASE INHIBITORS AND METHODS OF USE | |
| IL284661A (en) | pcsk9 inhibitors and methods of using them | |
| EP3983386A4 (en) | ACSS2 INHIBITORS AND METHODS OF USE | |
| EP3897622A4 (en) | ARGINASE INHIBITORS AND METHODS OF USE | |
| EP3735242A4 (en) | METALLO-BETA-LACTAMASE INHIBITORS AND THEIR METHODS OF USE | |
| EP3986894A4 (en) | ECTONUCLEOTIDASE INHIBITORS AND METHODS OF USE THEREOF | |
| PH12020551336A1 (en) | Anti-klk5 antibodies and methods of use | |
| EP3846808A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
| IL280924A (en) | Arginase inhibitors and methods of using them | |
| MX2021003731A (es) | Inhibidores de vap-1. | |
| EP3959197A4 (en) | PAPD5 INHIBITORS AND METHODS OF USE THEREOF | |
| MX2021016050A (es) | Formulaciones transdermicas. | |
| EP3781168A4 (en) | PAK4 INHIBITORS AND METHODS OF USE | |
| MX2022006577A (es) | Formulaciones liquidas de tasimelteon y metodos para su uso. | |
| CR20210463A (es) | Inhibidores de arginasa y métodos de uso de estos | |
| EP3793552A4 (en) | ABHD12 INHIBITORS AND METHODS OF MAKING AND USE THEREOF |